{"id":781997,"date":"2023-09-06T09:17:28","date_gmt":"2023-09-06T13:17:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"modified":"2023-09-06T09:17:28","modified_gmt":"2023-09-06T13:17:28","slug":"lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/","title":{"rendered":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference"},"content":{"rendered":"
\n

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) — LAVA<\/u>Therapeutics<\/u>N.V.<\/u><\/a>(Nasdaq:<\/u>LVTX<\/u><\/a>), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th<\/sup> Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET.<\/p>\n

A webcast of the fireside chat can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at:\u00a0https:\/\/ir.lavatherapeutics.com\/news-events\/events<\/a>. The replay will be archived for 90 days following the presentation date.<\/p>\n

\n About LAVA Therapeutics<\/strong>
\n
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V\u03b39V\u03b42 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. A Phase 1\/2a dose escalation clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling in Europe and the United States (NCT05369000<\/a>). The Company\u2019s collaborations include a license agreement with Seagen for the clinical development of SGN-EGFRd2 (LAVA-1223). For more information, please visit\u00a0www.lavatherapeutics.com<\/a>, and follow us on LinkedIn<\/a>, \u00a0X (formerly known as\u00a0Twitter<\/u><\/a>), and YouTube<\/a>.<\/p>\n

\n
\n CONTACTS<\/u>
\n <\/strong>
\n
Investor Relations
ir@lavatherapeutics.com<\/p>\n

Argot Partners (IR\/Media)
212-600-1902
lava@argotpartners.com<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET. A webcast of the fireside chat can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at:\u00a0https:\/\/ir.lavatherapeutics.com\/news-events\/events. The replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a … <\/p>\n

Continue reading “LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781997","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET. A webcast of the fireside chat can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at:\u00a0https:\/\/ir.lavatherapeutics.com\/news-events\/events. The replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a … Continue reading "LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-06T13:17:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference\",\"datePublished\":\"2023-09-06T13:17:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"},\"wordCount\":276,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\",\"name\":\"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=\",\"datePublished\":\"2023-09-06T13:17:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","og_description":"UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET. A webcast of the fireside chat can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at:\u00a0https:\/\/ir.lavatherapeutics.com\/news-events\/events. The replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is a … Continue reading \"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-06T13:17:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference","datePublished":"2023-09-06T13:17:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/"},"wordCount":276,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/","name":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=","datePublished":"2023-09-06T13:17:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzQ0NiM1Nzk5Njk0IzIyMDY3OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-participate-in-the-h-c-wainwright-25th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781997"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}